Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2316-2325

This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stalenhoef, A. F.H.
Right arrow Articles by Steinmetz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stalenhoef, A. F.H.
Right arrow Articles by Steinmetz, A.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2316-2325.)
© 1997 American Heart Association, Inc.


Articles

The 19th Annual Meeting of the European Lipoprotein Club

Anton F.H. Stalenhoef; Katriina Aalto-Setälä; Victor W. Armstrong; Pascale Benlian; Hans Dieplinger; Steve Humphries; ; Armin Steinmetz

Correspondence to Dr A.F.H. Stalenhoef, Department of Medicine, Division of General Internal Medicine 541, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands. E-mail A.Stalenhoef@aig.azn.nl


*    Introduction
 
The European Lipoprotein Club met September 9 to 12, 1996, in Tutzing, Germany. There were 99 participants from 13 European countries and the United States.

Dr Jonathan C. Fox from the University of Pennsylvania, Philadelphia, opened the meeting with a state-of-the-art lecture entitled "Cardiovascular Gene Therapy: Current Concepts." Gene therapy constitutes a novel therapeutic approach to selected cardiovascular diseases and is designed to augment traditional techniques of diagnosis and treatment by targeting the molecular mechanisms of disease.

Dr Fox first presented the general strategies driving the development of gene therapy. In the case of deleterious gene mutations causing disease, the defective gene can be replaced with a normal copy. In a pathophysiologic process that can be alleviated through augmented gene function, a beneficial gene can be overexpressed or a mutated "designer" gene, which is either more active or in some way more beneficial than its natural precursor, can be expressed. Normal genes may also confer therapeutic benefits by virtue of their expression in a novel environment. The expression of harmful genes can also be inhibited by antisense oligonucleotides, antisense RNA expression vectors, ribozymes, or triplex DNA. Dominant negative genes can be expressed, eg, encoding a protein that binds to regulatory partners but is not active. So-called decoy DNA, made up of short segments of double-stranded DNA encoding the recognition sequence for regulatory proteins such as transcription factors, can be delivered to cells, binding the transcription factors and, thereby, competing for their biologic targets and inhibiting their function.

The requirements for . . . [Full Text of this Article]